1.83 USD
+0.13 (+7.65%)
1.83 USD
0 (0%)
LCTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While LCTX seems to be doing ok healthwise, there are quite some concerns on its profitability. LCTX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
LCTX had negative earnings in the past year.
LCTX had a negative operating cash flow in the past year.
LCTX had negative earnings in each of the past 5 years.
LCTX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -45.06%, LCTX is in line with its industry, outperforming 54.53% of the companies in the same industry.
With a Return On Equity value of -84.55%, LCTX perfoms like the industry average, outperforming 50.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.06% | ||
| ROE | -84.55% | ||
| ROIC | N/A |
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LCTX has a Gross Margin of 97.55%. This is amongst the best in the industry. LCTX outperforms 97.17% of its industry peers.
In the last couple of years the Gross Margin of LCTX has grown nicely.
The Profit Margin and Operating Margin are not available for LCTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
2. Health
2.1 Basic Checks
LCTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LCTX has more shares outstanding
LCTX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, LCTX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.98, we must say that LCTX is in the distress zone and has some risk of bankruptcy.
LCTX has a Altman-Z score (-0.98) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.00 indicates that LCTX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, LCTX perfoms like the industry average, outperforming 51.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.98 |
ROIC/WACCN/A
WACC8.82%
2.3 Liquidity
A Current Ratio of 4.08 indicates that LCTX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.08, LCTX is in line with its industry, outperforming 49.25% of the companies in the same industry.
LCTX has a Quick Ratio of 4.08. This indicates that LCTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.08, LCTX is in line with its industry, outperforming 50.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.08 | ||
| Quick Ratio | 4.08 |
3. Growth
3.1 Past
LCTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -91.67%.
The Revenue has been growing slightly by 6.19% in the past year.
Measured over the past years, LCTX shows a very strong growth in Revenue. The Revenue has been growing by 21.96% on average per year.
EPS 1Y (TTM)-91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%-2.59%
3.2 Future
LCTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.57% yearly.
The Revenue is expected to grow by 60.92% on average over the next years. This is a very strong growth
EPS Next Y-211.1%
EPS Next 2Y16.07%
EPS Next 3Y6.4%
EPS Next 5Y25.57%
Revenue Next Year19.95%
Revenue Next 2Y64.1%
Revenue Next 3Y40.48%
Revenue Next 5Y60.92%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LCTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LCTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.07%
EPS Next 3Y6.4%
5. Dividend
5.1 Amount
LCTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.83
+0.13 (+7.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.2%
Inst Owner Change0%
Ins Owners5.39%
Ins Owner Change0.16%
Market Cap421.50M
Revenue(TTM)9.50M
Net Income(TTM)-40.91M
Analysts81.54
Price Target4.25 (132.24%)
Short Float %10.88%
Short Ratio12.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-65.65%
Min EPS beat(2)-152.86%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)-22.86%
Min EPS beat(4)-152.86%
Max EPS beat(4)54.25%
EPS beat(8)5
Avg EPS beat(8)-2.23%
EPS beat(12)8
Avg EPS beat(12)3.98%
EPS beat(16)9
Avg EPS beat(16)-13.64%
Revenue beat(2)1
Avg Revenue beat(2)31.49%
Min Revenue beat(2)-21.11%
Max Revenue beat(2)84.09%
Revenue beat(4)3
Avg Revenue beat(4)98.73%
Min Revenue beat(4)-21.11%
Max Revenue beat(4)258.54%
Revenue beat(8)6
Avg Revenue beat(8)55.6%
Revenue beat(12)8
Avg Revenue beat(12)37.83%
Revenue beat(16)11
Avg Revenue beat(16)51.08%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-13.67%
EPS NY rev (3m)-55.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.02%
Revenue NY rev (3m)14.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 38.62 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.71 | ||
| P/tB | 70.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.05
BVpS0.21
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -45.06% | ||
| ROE | -84.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.55% | ||
| FCFM | N/A |
ROA(3y)-19.65%
ROA(5y)-20.55%
ROE(3y)-31.15%
ROE(5y)-32.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.77%
GM growth 5Y1.84%
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 93.78% | ||
| Cap/Sales | 5.39% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.08 | ||
| Quick Ratio | 4.08 | ||
| Altman-Z | -0.98 |
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)82.11%
Cap/Depr(5y)57.88%
Cap/Sales(3y)5.42%
Cap/Sales(5y)5.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y-211.1%
EPS Next 2Y16.07%
EPS Next 3Y6.4%
EPS Next 5Y25.57%
Revenue 1Y (TTM)6.19%
Revenue growth 3Y29.84%
Revenue growth 5Y21.96%
Sales Q2Q%-2.59%
Revenue Next Year19.95%
Revenue Next 2Y64.1%
Revenue Next 3Y40.48%
Revenue Next 5Y60.92%
EBIT growth 1Y20.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.2%
EBIT Next 3Y2.48%
EBIT Next 5Y2.67%
FCF growth 1Y27.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.91%
OCF growth 3YN/A
OCF growth 5YN/A
LINEAGE CELL THERAPEUTICS IN / LCTX FAQ
What is the fundamental rating for LCTX stock?
ChartMill assigns a fundamental rating of 3 / 10 to LCTX.
What is the valuation status for LCTX stock?
ChartMill assigns a valuation rating of 0 / 10 to LINEAGE CELL THERAPEUTICS IN (LCTX). This can be considered as Overvalued.
What is the profitability of LCTX stock?
LINEAGE CELL THERAPEUTICS IN (LCTX) has a profitability rating of 2 / 10.
What is the expected EPS growth for LINEAGE CELL THERAPEUTICS IN (LCTX) stock?
The Earnings per Share (EPS) of LINEAGE CELL THERAPEUTICS IN (LCTX) is expected to decline by -211.1% in the next year.